INGELHEIM, Germany and INDIANAPOLIS, US--(BUSINESS WIRE)--EX US & UK. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are pleased to announce that less than two years after forming a strategic alliance aimed at bringing new treatments to patients with diabetes, the companies will present 30 abstracts across three compounds and three classes of medicine at the 72nd American Diabetes Association (ADA) Scientific Sessions in Philadelphia, June 8-12.
